<DOC>
	<DOCNO>NCT02644694</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) dexamethasone phosphate ophthalmic solution deliver via EyeGate® II Drug Delivery System ( EGDS ) patient undergo vitrectomy macular hole repair epiretinal membrane peeling</brief_summary>
	<brief_title>PK Study Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Patients Undergoing Vitrectomy</brief_title>
	<detailed_description>This open-label , multi-center , single-dose , Phase 1 clinical trial design evaluate pharmacokinetics ( PK ) dexamethasone phosphate ophthalmic solution deliver via EyeGate® II Drug Delivery System ( EGDS ) vitreous humor take patient undergo vitrectomy macular hole repair epiretinal membrane peeling</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Age 18 85 year 2 . Receive , understand , sign copy write informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>